ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Myelodysplastic syndrome (MDS) cytogenetic scoring system: International Prognostic Scoring System, Revised

Myelodysplastic syndrome (MDS) cytogenetic scoring system: International Prognostic Scoring System, Revised
Prognostic subgroups Cytogenetic abnormalities Percent of patients Survival
(years, median)		 AML evolution, 25 percent
(years, median)		 Hazard ratio OS Hazard ratio AML
Very good –Y, del(11q) 4 5.4 NR 0.7 0.4
Good Normal, del(5q), del(12p), del(20q), double including del(5q) 72 4.8 9.4 1 1
Intermediate del(7q), +8, +19, i(17q), any other single or double independent clones 13 2.7 2.5 1.5 1.8
Poor –7, inv(3)/t(3q)/del(3q), double including –7/del(7q), complex: 3 abnormalities 4 1.5 1.7 2.3 2.3
Very poor Complex: >3 abnormalities 7 0.7 0.7 3.8 3.6
AML: acute myeloid leukemia; OS: overall survival.
This research was originally published in Blood. Modified from: Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454-65. Copyright © 2012 American Society of Hematology.
Graphic 96321 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟